KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Capital Expenditures (2016 - 2025)

Emergent BioSolutions' Capital Expenditures history spans 16 years, with the latest figure at $12.0 million for Q4 2025.

  • For Q4 2025, Capital Expenditures rose 3900.0% year-over-year to $12.0 million; the TTM value through Dec 2025 reached $13.8 million, up 626.32%, while the annual FY2025 figure was $13.8 million, 626.32% up from the prior year.
  • Capital Expenditures reached $12.0 million in Q4 2025 per EBS's latest filing, up from -$400000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $233.7 million in Q4 2022 to a low of -$102.5 million in Q3 2021.
  • Average Capital Expenditures over 5 years is $26.8 million, with a median of $6.2 million recorded in 2023.
  • Peak YoY movement for Capital Expenditures: plummeted 216.21% in 2021, then skyrocketed 4700.0% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $203.5 million in 2021, then rose by 14.84% to $233.7 million in 2022, then crashed by 95.12% to $11.4 million in 2023, then crashed by 97.37% to $300000.0 in 2024, then surged by 3900.0% to $12.0 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Capital Expenditures are $12.0 million (Q4 2025), -$400000.0 (Q3 2025), and -$1.4 million (Q2 2025).